These IL13-zetakine CAR T cells were specifically and potently activated in the presence of IL13Rα2-expressing glioma cells, whereas no appreciable effect was seen in the absence of IL13Rα2 expression. The gene discussed is IL13; the disease is central nervous system cancer.